Industry News

Eylea shows sustained improvements in BCVA vs. laser photocoagulation

Data from the phase 3 VIVID-DME trial indicate that aflibercept injection provided sustained improvements in best corrected visual acuity from baseline at 2 years compared with laser photocoagulation in patients with diabetic macular edema.

Patients in the VIVID-DME trial were randomly assigned to either aflibercept (Eylea, Regeneron) 2 mg monthly, aflibercept 2 mg every 2 months or the comparator treatment of laser photocoagulation.

In patients who received aflibercept 2 mg monthly, 2-year data indicated a mean change in BCVA from baseline of 11.4 letters (10.5 letters at 52 weeks, P < .0001 vs. laser), according to a company press release.

Patients assigned to aflibercept 2 mg every 2 months had a mean change in BCVA from baseline of 9.4 letters (10.7 letters at 52 weeks, P < .0001 vs. laser).

The most common adverse events included conjunctival hemorrhage, cataract and increased IOP, according to the release.

Full 2-year data from the VIVID-DME trial will be presented at an upcoming scientific conference, according to the release.

Data from the phase 3 VIVID-DME trial indicate that aflibercept injection provided sustained improvements in best corrected visual acuity from baseline at 2 years compared with laser photocoagulation in patients with diabetic macular edema.

Patients in the VIVID-DME trial were randomly assigned to either aflibercept (Eylea, Regeneron) 2 mg monthly, aflibercept 2 mg every 2 months or the comparator treatment of laser photocoagulation.

In patients who received aflibercept 2 mg monthly, 2-year data indicated a mean change in BCVA from baseline of 11.4 letters (10.5 letters at 52 weeks, P < .0001 vs. laser), according to a company press release.

Patients assigned to aflibercept 2 mg every 2 months had a mean change in BCVA from baseline of 9.4 letters (10.7 letters at 52 weeks, P < .0001 vs. laser).

The most common adverse events included conjunctival hemorrhage, cataract and increased IOP, according to the release.

Full 2-year data from the VIVID-DME trial will be presented at an upcoming scientific conference, according to the release.